2022 American Transplant Congress

June 4-8, 2022 in Boston, MA

The ATC program is built in the Eastern Time Zone.

View by Title View Sessions View Topics

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Impact of Cyp 3a5 Genotype on Lcp Tacrolimus Dosing and Monitoring in Kidney Transplantation

D. J. Taber, T. Carcella, N. Patel, F. Bartlett, A. Posadas, V. Rao, M. Casey, V. Rohan, D. Dubay, D. Taber
Impact of Cytomegalovirus and BK Virus Infection on Clinical Outcomes in Kidney Transplant Recipients

W. Park, J. Yang, J. Kwon, J. Lim, Y. Kim, J. Paek, K. Jin, S. Han
Impact of Cytomegalovirus Infection on mRNA Expression Utilizing the Molecular Microscope in Heart Transplant Recipients

S. S. Patlolla, J. Van Zyl, K. Castro, S. Mckean, R. Patel, S. Carey, A. Alam, S. Hall
Impact of Delayed Graft Function in Donation After Circulatory Death Kidney Transplantation

J. Mello Offerni¹, H. Brar¹, D. Lee¹, M. Levine², M. Mandurah¹, S. Rim¹, A. Sener¹, P. Luke¹
Impact of Donor and Recipient Characteristics on Early Post-Transplant Donor-Derived Cell-Free DNA (dd-cfDNA) Scores

A. Alam¹, J. Zeng², J. Teuteberg³, S. Hall¹
Impact of Donor Quality on Outcomes for AKI and Non-AKI Kidneys with and without DGF

C. Jadlowiec¹, P. Budhiraja², R. Butterfield¹, M. Smith³, A. K. Mathur¹, A. Moss¹, H. Khamash², K. Reddy¹, R. Heilman²
Impact of Donor Type, Cold Ischemia Time, and Induction Type on Baseline Donor-Derived Cell-Free DNA in Kidney Transplant Recipients

K. K. Sureshkumar¹, A. Grazier², B. Chopra¹
Impact of Donor-Recipient Age Discrepancy in Living Donor Kidney Transplantation – The Need for Better Matching

N. K. Prabhu¹, V. Villani¹, K. P. Samy¹, D. Sudan¹, K. Ravindra¹, W. Irish²
Impact of Donor-to-Recipient Body Surface Area Ratio on Graft Survival and Mortality Following Deceased Donor Liver Transplants

S. Radomski, L. Zeiser, A. Massie, S. Ottmann, D. Segev, E. King
Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial

F. Silveira¹, S. Haider², D. Kaul³, O. Witzke⁴, J. Gu⁵, A. Sundberg⁵

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z